PROS1 and COVID-19: However, CVnCoV, the unmodified mRNA vaccine with naturally occurring nucleotides encoding the full-length S protein failed to provide the minimum efficacy in Phase III trials with only 48% protection against COVID-19 (CureVac, 2021; Kremsner et al., 2021).